A novel activating <i>JAK1</i> mutation in chronic eosinophilic leukemia
William Shomali(Stanford Medicine), Jason Gotlib(Stanford University), Alisa Damnernsawad(Oregon Health & Science University), Richard D. Press(Oregon Health & Science University), Jeffrey Tyner(Oregon Health & Science University), Sebastian Fernandez‐Pol(Stanford University), Quinlan Morrow(Oregon Health & Science University), Fei Yang(Peking University), Talent Theparee(University of California, San Francisco), David A. Sampson(Oregon Health & Science University), James L. Zehnder(Cancer Prevention Institute of California)
Cited by 20
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia
|Cancer Cell|2014|366
Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signals
|Journal of Clinical Investigation|2006|260
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
|Haematologica|2015|252
An expanded universe of cancer targets
|Cell|2021|221